Patents by Inventor Rajinder Singh

Rajinder Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATORS OF ION CHANNEL RECEPTORS AND USES THEREOF
    Publication number: 20220251099
    Abstract: Compounds useful in the modulation of ion channel activity in cells are disclosed herein. This disclosure also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Application
    Filed: April 20, 2022
    Publication date: August 11, 2022
    Inventors: Belinda HUFF, Courtney HOLLIS, Hamish TOOP, Nathan KUCHEL, Lorna Helen MITCHELL, Rajinder SINGH
  • METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS
    Publication number: 20220241290
    Abstract: The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist.
    Type: Application
    Filed: September 22, 2021
    Publication date: August 4, 2022
    Inventors: James J. CAMPBELL, Rajinder SINGH, Samuel HWANG, Xuesong WU
  • METHOD OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS
    Publication number: 20220226294
    Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.
    Type: Application
    Filed: April 8, 2022
    Publication date: July 21, 2022
    Inventors: Zhenhua MIAO, Thomas SCHALL, Rajinder SINGH
  • COMPOUNDS AND METHOD FOR TREATING AUTOIMMUNE DISEASES
    Publication number: 20220218705
    Abstract: Compounds and embodiments of a method for treating and/or preventing autoimmune diseases are disclosed. The method includes administering to a subject having an autoimmune disease, such as an inflammatory bowel disease, a therapeutically effective amount of a compound according to formula I wherein X and Y independently are O or NR1; each R1 is independently H or C1-C6 alkyl; ring A is aryl; each R2 independently is H, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, or two R2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; p is 0, 1, 2, 3, or 4; R3 and R4 independently are H or C1-C6 alkyl; and R5 is halo, cyano, or C1-C6 alkyl.
    Type: Application
    Filed: December 10, 2021
    Publication date: July 14, 2022
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Rajinder Singh, Vanessa Taylor, Donald G. Payan
  • SEALING APPARATUS FOR A LATERALLY-SLIDING DOOR
    Publication number: 20220219518
    Abstract: Disclosed embodiments include seals, vehicles, and methods for providing a seal for a door that is configured to travel laterally relative to a door opening. In an illustrative embodiment, a seal assembly includes first and second upper and lower lateral seals configured to seal outer and inner surfaces of the upper and lower edges of the door, respectively, as the door laterally moved into a closed position. The seal includes first and second front and rear transverse seals configured to seal the outer and the inner surfaces of the front and rear edges of the door, respectively, in response to the door laterally moving into the closed position.
    Type: Application
    Filed: January 12, 2021
    Publication date: July 14, 2022
    Inventors: Rajinder Singh, Rick Bargardi, Mohit Nagallapuram, Jeffrey D. Elliott, David Tobon
  • Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
    Patent number: 11382915
    Abstract: Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor. The CCR2 antagonist may have the structure of formula (I).
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: July 12, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Zhenhua Miao, Thomas J. Schall, Rajinder Singh
  • 6-5 fused rings as C5a inhibitors
    Patent number: 11384079
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: July 12, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • Modulators of ion channel receptors and uses thereof
    Patent number: 11384085
    Abstract: Compounds useful in the modulation of ion channel activity in cells are disclosed herein. This disclosure also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: July 12, 2022
    Assignee: BIONOMICS LIMITED
    Inventors: Belinda Huff, Courtney Hollis, Hamish Toop, Nathan Kuchel, Lorna Helen Mitchell, Rajinder Singh
  • Pyrazole compounds and methods for making and using the compounds
    Patent number: 11370808
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: June 28, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ryan Kelley, Hui Li, Thilo Heckrodt, Yan Chen, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • Gene controlling shell phenotype in palm
    Patent number: 11371104
    Abstract: Nucleic acid sequences for predicting and controlling shell phenotype in palm.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: June 28, 2022
    Assignee: Malaysian Palm Oil Board
    Inventors: Rajinder Singh, Leslie Low Eng Ti, Leslie Ooi Cheng Li, Meilina Ong Abdullah, Rajanaidu Nookiah, Ravigadevi Sambanthamurthi, Steven W. Smith, Nathan D. Lakey, Rob Martienssen, Jared Ordway, Michael Hogan
  • BENZAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS
    Publication number: 20220185804
    Abstract: Disclosed are novel benzazole compounds and compositions comprising the compounds. The compounds are useful as kinase inhibitors including interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Application
    Filed: March 7, 2022
    Publication date: June 16, 2022
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Rose Yen, Yan Chen, Rajinder Singh, Vanessa Taylor
  • INDANE-AMINES AS PD-L1 ANTAGONISTS
    Publication number: 20220175746
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: August 30, 2021
    Publication date: June 9, 2022
    Inventors: Christopher LANGE, Sreenivas PUNNA, Rajinder SINGH, Ju YANG, Penglie ZHANG
  • TGF-beta inhibitors
    Patent number: 11352360
    Abstract: Disclosed are imidazole and thiazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, A, Z, R1 and R? are as described herein. In certain embodiments, a compound disclosed herein inhibits TGF-?, and can be used to treat disease by blocking TGF-? signaling.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: June 7, 2022
    Assignees: Rigel Pharmaceuticals, hic., Bristol-Myers Squibb Company
    Inventors: Todd Kinsella, Marina Gelman, Hui Hong, Ihab S. Darwish, Rajinder Singh, Jiaxin Yu, Robert M. Borzilleri, Upender Velaparthi, Peiying Liu, Chetan Padmakar Dame, Hasibur Rahaman, Jayakumar Sankara Warrier
  • Method of Treating Focal Segmental Glomerulosclerosis
    Patent number: 11324736
    Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: May 10, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Zhenhua Miao, Thomas Schall, Rajinder Singh
  • METHODS OF TREATING HIDRADENITIS SUPPURATIVA
    Publication number: 20220125775
    Abstract: Provided herein are methods for treating a subject suffering from a cutaneous neutrophilic inflammatory disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein each variable position is as defined herein. In some embodiments, the cutaneous neutrophilic inflammatory disease is Hidradenitis suppurativa (HS).
    Type: Application
    Filed: October 27, 2021
    Publication date: April 28, 2022
    Inventors: Shijie LI, Rajinder Singh, Thomas J. Schall, Peter Staehr
  • MACROCYCLIC IMMUNOMODULATORS
    Publication number: 20220119405
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R6c, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: June 3, 2021
    Publication date: April 21, 2022
    Inventors: Viengkham MALATHONG, Jeffrey McMAHON, Darren J. McMURTRIE, Sreenivas PUNNA, Howard S. ROTH, Rajinder SINGH, Penglie ZHANG
  • Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
    Patent number: 11304952
    Abstract: The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: April 19, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: James J. Campbell, Zhenhua Miao, Thomas J. Schall, Israel Charo, Shijie Li, Christine Marie Janson, Rajinder Singh, Karen Ebsworth
  • SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20220112176
    Abstract: The present disclosure relates generally to compounds useful for the treatment and/or enhancement of cognitive function and negative symptoms associated with central nervous system disorders where the circuitry involving fast spiking PV+ interneurons and the production of cortical gamma oscillations is disrupted. The subject disclosure enables the manufacture of medicaments as well as compositions containing same for use in methods of therapy and prophylaxis of cognitive dysfunction and negative symptoms.
    Type: Application
    Filed: October 30, 2019
    Publication date: April 14, 2022
    Inventors: Hamish Toop, Dharam Paul, Rajinder Singh, Erin Smith, Patrick Bazzini, Jean-Marie Contreras, Christophe Morice, Laurent Schaeffer, Celine Michaut-Simon, Florence Chery, Fabrice Garrido
  • Benzazole compounds and methods for making and using the compounds
    Patent number: 11299486
    Abstract: Disclosed are novel benzazole compounds and compositions comprising the compounds. The compounds are useful as kinase inhibitors including interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: April 12, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rose Yen, Yan Chen, Rajinder Singh, Vanessa Taylor
  • FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR
    Publication number: 20220096453
    Abstract: Provided herein is a free base crystalline form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the crystalline free base form of Compound 1 described herein.
    Type: Application
    Filed: May 4, 2021
    Publication date: March 31, 2022
    Inventors: Rajinder SINGH, Kwok YAU, Yibin ZENG, Penglie ZHANG, Rebecca M. LUI, Antoni KRASINSKI